Skip to search formSkip to main contentSkip to account menu

ambrisentan

Known as: 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid, ambrisentan [Chemical/Ingredient], (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

Antihypertensive AgentsPhenylpropionatesPyridazines

Narrower (2)

BSF 208075LU 208075
ambrisentan 5 MG Oral Tablet [Letairis]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists
Pulmonary arterial hypertension (PAH) is a group of diseases characterized by a progressive increase of pulmonary vascular… 
2013
2013
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1
We assessed the effect of cytochrome P450 (CYP) 3A4 and the OATP1B1 inhibitor clarithromycin on ambrisentan steady-state kinetics… 
2012
2012
Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.
2012
2012
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension
Introduction: Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance, which can… 
Review
2011
Review
2011
Endothelin receptor antagonists -- their role in pulmonary medicine.
Review
2011
Review
2011
Pharmacokinetic evaluation of ambrisentan
Introduction: Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease characterized by increasing… 
2010
2010
Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects
AbstractBackground: Ambrisentan is a once-daily, endothelin (ET) type A receptor-selective antagonist approved for the treatment… 
2009
2009
Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan
Ambrisentan is an endothelin type A (ETA)–selective receptor antagonist that is metabolized primarily by glucuronidation but also… 
2007
2007
EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils
Review
2002
Review
2002
Ambrisentan (Myogen).
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)